Blogs
Healthcare and Medtech Research Reports
Nov 17, 2026
Johnson & Johnson Announces Positive Phase 3 Results for CAPLYTA in Bipolar Mania Johnson & Johnson announced positive results from Study 452, the second pivotal Phase 3 trial assessing CAPLYTA (lumateperone) for the treatment of manic episodes, with or without mixed features, in adults with bipolar I di...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper